2. Search Result
Search Result
Results for "

Breast Cancer,

" in MedChemExpress (MCE) Product Catalog:

2334

Inhibitors & Agonists

4

Screening Libraries

33

Fluorescent Dye

40

Biochemical Assay Reagents

91

Peptides

2

MCE Kits

113

Inhibitory Antibodies

336

Natural
Products

7

Recombinant Proteins

68

Isotope-Labeled Compounds

12

Antibodies

26

Click Chemistry

36

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17026
    Gemcitabine
    265+ Cited Publications

    LY 188011

    		 Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis p38 MAPK Infection Inflammation/Immunology Cancer
    Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, and can modulate autophagy. Gemcitabine induces apoptosis through the activation of p38 MAPK. Gemcitabine demonstrates efficacy in mouse models of pancreatic and breast cancer. Gemcitabine can be used for cancer research, such as pancreatic cancer, non-small cell lung cancer, and breast cancer .
    Gemcitabine
  • HY-14590
    Kaempferol
    Maximum Cited Publications
    76 Publications Verification

    Kempferol; Robigenin

    		 Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite Cancer
    Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer .
    Kaempferol
  • HY-P9907A
    Trastuzumab (anti-HER2)
    Maximum Cited Publications
    55 Publications Verification

    Anti-Human HER2, Humanized Antibody (anti-HER2)

    		 ADC Antibody EGFR Cancer
    Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab (anti-HER2)
  • HY-108692
    Enterolactone

    		Apoptosis Endogenous Metabolite Cancer
    Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity . Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis .
    Enterolactone
  • HY-14590R
    Kaempferol (Standard)
    Maximum Cited Publications
    76 Publications Verification

    Kempferol(Standard); Robigenin (Standard)

    		 Reference Standards Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite Cancer
    Kaempferol (Standard) is the analytical standard of Kaempferol. This product is intended for research and analytical applications. Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer .
    Kaempferol (Standard)
  • HY-176444
    CDK2 degrader 6

    		Molecular Glues CDK Cancer
    CDK2 degrader 6 is an orally active and potent CDK2 molecular glue degrader with a DC50 of 46.5 nM. CDK2 degrader 6 binds to cereblon and CDK2 to induce ubiquitination and subsequent proteasomal degradation of CDK2. CDK2 degrader 6 modulates cell cycle in breast cancer cells. CDK2 degrader 6 reduces proliferation of breast cancer cells. CDK2 degrader 6 exhibits in vivo antitumor activity in gastric cancer mouse models. CDK2 degrader 6 can be used for the research of breast cancer, gastric cancer .
    CDK2 degrader 6
  • HY-111645
    3-Methylcytidine
    3 Publications Verification

    		 Nucleoside Antimetabolite/Analog Cancer
    3-Methylcytidine, a urinary nucleoside, can be used as a biomarker of four different types of cancer: lung cancer, gastric cancer, colon cancer, and breast cancer .
    3-Methylcytidine
  • HY-107967
    Isosulfan blue

    		Fluorescent Dye Cancer
    Isosulfan blue is a blue dye for the identification of lymph vessels during lymphangiography. Isosulfan blueis is used during sentinel lymph node biopsies in breast cancer. Isosulfan blue is possible to have an allergic reaction during breast cancer operations .
    Isosulfan blue
  • HY-13724B
    Pipendoxifene hydrochloride

    		Estrogen Receptor/ERR Cancer
    Pipendoxifene hydrochloride is a selective estrogen receptor modulator (SERM) that can be used for the research of breast cancer .
    Pipendoxifene hydrochloride
  • HY-16916
    NS1643
    1 Publications Verification

    		 Potassium Channel Autophagy Cancer
    NS1643 is a partial agonist of human ether-a-go-go-related gene (hERG) K + channels with an EC50 of 10.5 μM. NS1643 inhibits the growth of breast cancer tumors in TNBC mouse models. NS1643 inhibits cell migration and invasion of breast cancer cells .
    NS1643
  • HY-14586
    Irosustat
    1 Publications Verification

    STX64; BN83495; 667-Coumate

    		 Steroid Sulfatase Cancer
    Irosustat is a potent steroid sulfatase inhibitor, with an IC50 of 8 nM, and exhibits anti-breast cancer activity.
    Irosustat
  • HY-P990552A
    huATN-658

    		PAI-1 Integrin Cancer
    huATN-658 is an inhibitor that specifically targets the DIII domain of human urokinase plasminogen activator receptor (uPAR). huATN-658 neutralizes uPAR function by blocking the interaction between uPAR and integrins, without interfering with the binding of uPA or vitronectin to uPAR. huATN-658 inhibits the proliferation and invasion of breast cancer cells, slows the growth of primary breast tumors, reduces breast cancer-induced bone lesions and decreases osteoclast activity. huATN-658 also alters the gene expression of the TGF-β receptor complex signaling pathway. huATN-658 exerts synergistic anticancer effects when combined with Zoledronic Acid (HY-13777), and does not cause physiological or behavioral abnormalities in immunodeficient mice. huATN-658 can be used in research related to breast cancer, metastatic breast cancer and breast cancer-induced bone disease .
    huATN-658
  • HY-N6819
    Iristectorin B

    		Others Cancer
    Iristectorin B is an isoflavone from Iris tectorum, has anti-cancer activities in breast cancer .
    Iristectorin B
  • HY-W016582
    Methyl 2-(bromomethyl)acrylate

    		Biochemical Assay Reagents Cancer
    Methyl 2-(bromomethyl)acrylate is a biochemical Assay Reagents .Methyl 2-(bromomethyl)acrylate inhibits cell proliferation in breast cancer and pancreatic cancer cells. Methyl 2-(bromomethyl)acrylate can be used for the research of breast cancer and pancreatic cancer .
    Methyl 2-(bromomethyl)acrylate
  • HY-120069
    APX2009

    		Apoptosis Cancer
    APX2009 is a specific APE1/REF-1 redox inhibitor with anticancer activities which decreases the proliferative, migratory, and invasive properties of breast cancer cell and induces apoptosis in breast cancer cell .
    APX2009
  • HY-147526
    RM-581

    		Apoptosis Cancer
    RM-581, aminosteroid, is an orally active anticancer agent. RM-581 shows anticancer potency against pancreatic, breast, prostate, and ovarian cancers. RM-581 induces endoplasmic reticulum stress and apoptosis via disturbance of cancer cell cholesterol homeostasis. RM-581 can be used for the research of cancer, such as prostate cancer and breast cancer .
    RM-581
  • HY-153588
    HSP90-IN-22

    		HSP Cancer
    HSP90-IN-22 (Compound 35) is an Hsp90 inhibitor with antiproliferative properties on cells with IC50 values of 3.65 μM for MCF7 breast cancer cells and 2.71 μM for SKBr3 breast cancer cells, respectively.
    HSP90-IN-22
  • HY-169903
    SMIP34

    		Apoptosis Cancer
    SMIP34 is a PELP1 inhibitor. SMIP34 binds to PELP1 with a Kd of 37.4 μM. SMIP34 inhibits cancer cell proliferation and tumor progression. SMIP34 can be used for breast cancer research, and is active against wild-type (WT), mutant (MT) ER+ and therapy-resistant (TR)-ER+ breast cancer .
    SMIP34
  • HY-145716
    Nafoxidine

    Nafoxidene

    		 Estrogen Receptor/ERR Cancer
    Nafoxidine, a nonsteroidal estrogen antagonist, is shown to possess antitumor activity against breast cancer.
    Nafoxidine
  • HY-148368
    CYD-4-61

    		Bcl-2 Family Apoptosis Cancer
    CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis .
    CYD-4-61
  • HY-N6820
    Iristectorin A

    		Others Cancer
    Iristectorin A, a natural product from Iris tectorum, has anti-cancer activities in breast cancer .
    Iristectorin A
  • HY-172664
    Trabectedin derivative 2

    		Drug Derivative Cancer
    Trabectedin derivative 2 (compound PL-12) is a trabectedin derivative that can be used in research on ovarian cancer, gastric cancer, and breast cancer .
    Trabectedin derivative 2
  • HY-175988
    DNMT/HDAC-IN-2

    		DNA Methyltransferase HDAC Cancer
    DNMT/HDAC-IN-2 (Compound Y7) is a DNMT and HDAC inhibitor with IC50 values for DNMT1, HDAC1, and HDAC6 of 365, 0.2, and 8.91 nM respectively. DNMT/HDAC-IN-2 inhibits the proliferation of breast cancer cells. DNMT/HDAC-IN-2 significantly reduces tumor growth in xenografts and transgenic breast cancer mouse models. DNMT/HDAC-IN-2 can be used for the study of breast cancer .
    DNMT/HDAC-IN-2
  • HY-175865
    HSP70-IN-7

    		HSP Apoptosis Cancer
    HSP70-IN-7 is a nonselective HSP70 inhibitor with Kds of 4.71, 2.16 and 2.93μM against HSP70, GRP75, and GRP78. HSP70-IN-7 exhibits selective toxicity against breast cancer cells, induces cell apoptosis and effectively suppresses the properties of breast cancer stem cells (BCSCs). HSP70-IN-7 can be used for the study of breast cancer .
    HSP70-IN-7
  • HY-19671
    Apomine

    SR-45023A; SR 9223i; SK&F-99085

    		 HMG-CoA Reductase (HMGCR) Apoptosis Cancer
    Apomine (SR-45023A) is an orally active antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer .
    Apomine
  • HY-175809
    SRT6

    		CD44 Src EGFR MAPKAPK2 (MK2) Cancer
    SRT6 is a CD44 inhibitor. SRT6 exerts antiproliferative activity in CD44 + breast cancer and lung cancer cells. SRT6 inhibits CD44-associated SRC kinase, as well as EGFR, ERBB2, ERBB4, MAP3K10 and MAPKAPK2. SRT6 can be used for the research of breast cancer and lung cancer .
    SRT6
  • HY-122664
    XMU-MP-2

    		BRK Apoptosis STAT ERK Akt Cancer
    XMU-MP-2 is a selective BRK/PTK6 inhibitor with an IC50 of 5.4 nM. XMU-MP-2 inhibits the proliferation of BRK-positive breast cancer cells and induces apoptosis. XMU-MP-2 is applicable to breast cancer-related research .
    XMU-MP-2
  • HY-W587738
    Viridiflorol

    		Apoptosis Cancer
    Viridiflorol is an active natural molecule with anti-cancer effect. Viridiflorol induces anti-neoplastic effects on breast (MCF-7, IC50 = 10 µM), lung (A549, IC50 = 30 µM), and brain (Daoy, IC50 = 0.1 µM) cancer cells through apoptosis. Viridiflorol can be used for breast, lung, and brain cancer research .
    Viridiflorol
  • HY-175846
    TQFL13

    		Drug Derivative Apoptosis Cancer
    TQFL13 is derivative of Thymoquinone (TQ) (HY-D0803) with potent anti-breast cancer activity. TQFL13 exhibits higher cytotoxicity against breast cancer cells (BT549, MDA-MB-231, 4T1). TQFL13 increases apoptosis and blocks the cell cycle at S and G2/G1 phases in breast cancer cells. TQFL13 shows dose-dependent anti-tumor efficacy in mouse breast cancer allograft model. TQFL13 can be used for the study of breast cancer .
    TQFL13
  • HY-P11197
    ACT1

    		Gap Junction Protein Cancer
    ACT1 is a peptide that targets endogenous Cx43 by stabilizing its activity at gap junctions. ACT1 stabilizes gap junction intercellular communication in breast cancer cells. ACT1 enhances the activity of Tamoxifen (HY-13757A) and Lapatinib (HY-50898) in breast cancer. ACT1 can be used for breast cancer research .
    ACT1
  • HY-122878
    HS-131

    		HSP Cancer
    HS-131, a near infrared dye tethered Hsp90 inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers .
    HS-131
  • HY-176166
    PD-M6

    		mTOR PROTACs Autophagy Cancer
    PD-M6 is a mTOR PROTAC degrader (DC50: 4.8 μM). PD-M6 promotes ubiquitination and degradation of mTOR. PD-M6 downregulates MAPKAP1 and CASTOR1, and induces Autophagy. PD-M6 inhibits the proliferation of cervical cancer, breast cancer and liver cancer cell lines. PD-M6 can be used for the research of cervical cancer, breast cancer and liver cancer .
    PD-M6
  • HY-N7424
    4,7-Dihydroxycoumarin

    4,7-DHC

    		 EGFR Estrogen Receptor/ERR Progesterone Receptor Cancer
    4,7-Dihydroxycoumarin is an EGFR inhibitor, estrogen receptor inhibitor, and progesterone receptor inhibitor. 4,7-Dihydroxycoumarin against breast cancer cells with an IC50 velue of 18.36 μg/mL. 4,7-Dihydroxycoumarin can be used for the research of breast cancer .
    4,7-Dihydroxycoumarin
  • HY-P10790
    Breast cancer targeting peptide 18–4

    		Microtubule/Tubulin Cancer
    Breast cancer targeting peptide 18–4 is a KRT1 receptor-targeting peptide, with a Kd of 0.98 μM. The amino acid sequence of Breast cancer targeting peptide 18–4 is WxEAAYQrFL, and it is an analogue of P160 peptide (HY-P10789). When covalently conjugated with the anticancer peptide MccJ25, Breast cancer targeting peptide 18–4 significantly increases the cellular uptake of MccJ25 in breast cancer cells and enhances its anticancer activity. The covalent conjugate exhibits IC50 values of 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR cells, respectively .
    Breast cancer targeting peptide 18–4
  • HY-103043
    Pz 285

    		Others Cancer
    Pz 285 is an anti-cancer agent. Pz 285 shows significant inhibitory effect on the viability of MDA-MB-231 breast cancer cells, with an IC50 of 15.0 μM. Pz 285 exhibits remarkable antitumor effects in the mouse tumor xenograft model constructed with highly lung-metastatic MDA-MB-231 LM24 Her2+ breast cancer cells. Pz 285 can be used for the study of breast cancer, especially metastatic breast cancer .
    Pz 285
  • HY-P11265
    YQGN-7

    		GnRH Receptor Fluorescent Dye Cancer
    YQGN-7 is a targeted fluorescent probe for the gonadotropin-releasing hormone receptor (RnRHR). YQGN-7 exhibits high selectivity and affinity for breast cancer cells (KD = 217.8 nM). YQGN-7 achieves precise visualization of the primary and metastatic lesions of breast cancer by targeting the highly expressed GnRHR in tumor cells. YQGN-7 can be used in the research of breast cancer breast-conserving surgery (BCS) .
    YQGN-7
  • HY-P10789
    P160 peptide

    		Microtubule/Tubulin Cancer
    The P160 peptide is a breast cancer-targeting peptide that binds to the keratin 1 (KRT1) receptor on breast cancer cells, with a Kd of approximately 1.1 μM, demonstrating significant potential for targeted drug delivery to breast cancer cells. The P160 peptide enhances the cellular uptake and anticancer activity of the pro-apoptotic antimicrobial peptide MccJ25 (microcin J25). The P160 peptide can be used in cancer research .
    P160 peptide
  • HY-178349
    P-gp inhibitor 30

    		P-glycoprotein Apoptosis Autophagy Cancer
    P-gp inhibitor 30 is a potent P-gp inhibitor that reverses multidrug resistance in breast cancer by sensitizing resistant cells to Doxorubicin (ADM) (HY-15142). P-gp inhibitor 30 promotes apoptosis, induces autophagy, and suppresses proliferation, migration, and invasion of drug-resistant breast cancer cells when combined with ADM. P-gp inhibitor 30 inhibits breast tumor growth both in vitro and in vivo. P-gp inhibitor 30 can be used for drug-resistant breast cancer research .
    P-gp inhibitor 30
  • HY-175269
    MGB1Y

    		DNA Alkylator/Crosslinker DNA/RNA Synthesis Topoisomerase Cancer
    MGB1Y is a noncovalent DNA minor groove binder (MGB). MGB1Y potently inhibits cancer cells proliferation and topoisomerase I activity. MGB1Y downregulates their breast cancer-related genes in MCF7 and MDA-MB-231 cells. MGB1Y has a broad-spectrum anticancer activity, such as breast cancer, colon cancer, and leukemia .
    MGB1Y
  • HY-157151
    iPRMT1

    		Histone Methyltransferase Cancer
    iPRMT1 is a potent and selective PRMT1 inhibitor for breast cancer research. iPRMT1 inhibits breast cancer cell growth in vitro and in vivo with EC50 values of 90, 70, and 9 nM in MCF7, T47D, and MDA-MB-231 cells, respectively .
    iPRMT1
  • HY-149469
    3,7,2',4'-Tetramethoxy-5-hydroxyflavone

    		BCRP Cancer
    BCRP/ABCG2-IN-1 is the inhibitor of breast cancer resistance protein (BCRP/ABCG2), with IC50 of 5.98 μM, that can be used in multidrug resistance of breast cancer .
    3,7,2',4'-Tetramethoxy-5-hydroxyflavone
  • HY-125575
    FC11409B

    		Carbonic Anhydrase Cancer
    FC11409B is an ureido-sulfamate carbonic anhydrase IX (CAIX) inhibitor. FC11409B inhibits proliferation and migration of breast cancer cell lines in both hypoxic (0.5% O2) and normoxic conditions (21% O2). FC11409B also inhibits 3D spheroid of breast cancer subtypes invasion. FC11409B is promising for research of breast and ovarian cancers .
    FC11409B
  • HY-160049
    BC15 aptamer sodium

    		Nucleoside Antimetabolite/Analog Biochemical Assay Reagents Cancer
    BC15 aptamer sodium is an ssDNA aptamer targeting the intracellular protein hnRNP A1, which is highly expressed in cancerous liver tissue. BC15 aptamer sodium specifically recognizes breast cancer cells and can be used to detect cancer cells in other pathological types of breast cancer tissue .
    BC15 aptamer sodium
  • HY-P2745
    Glycerophosphocholine phosphodiesterase

    GPC-PDE

    		 Biochemical Assay Reagents Cancer
    Glycerophosphocholine phosphodiesterase (GPC-PDE) catalyzes the degradation of low-glycerophosphocholine into free choline and glycerol-3-phosphate. Glycerophosphocholine phosphodiesterase participates in the regulation of choline phospholipid metabolism in breast cancer. Glycerophosphocholine phosphodiesterase can be used for research on diseases such as breast cancer .
    Glycerophosphocholine phosphodiesterase
  • HY-W087006
    p-Hydroxyphenylacetone

    		Androgen Receptor Cancer
    p-Hydroxyphenylacetone, a Raspberry ketone (HY-N1426) derivative, is an androgen receptor (AR) antagonist with an IC50 of 420 μM in MDA-kb2 human breast cancer cells. p-Hydroxyphenylacetone can be used for breast cancer research .
    p-Hydroxyphenylacetone
  • HY-135606
    LW479

    		HDAC Cancer
    LW479, a novel HDAC inhibitor, could be a candidate agent for breast cancer prevention.
    LW479
  • HY-153909
    SMP-33693

    		Drug-Linker Conjugates for ADC Cancer
    SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
    SMP-33693
  • HY-P10445
    TAT-PiET

    		Epigenetic Reader Domain Cancer
    TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET can reduce BRD4 and JMJD6 levels and inhibit cell proliferation. TAT-PiET also resists the endocrine resistance of ERα-positive breast cancer cells. TAT-PiET can be used for the research of cancer, such as breast cancer .
    TAT-PiET
  • HY-175981
    Paclitaxel-bromothiophene

    		Drug Derivative Cancer
    Paclitaxel-bromothiophene is a semisynthetic taxane analogue of Paclitaxel (HY-B0015). Paclitaxel-bromothiophene exhibits potent antiproliferative activity against 4-T1 breast cancer cells, with an IC50 value of 15.18 nM. Paclitaxel-bromothiophene shows high binding affinity to C5aR1 (Kd = 19.4 μM). Paclitaxel-bromothiophene demonstrates excellent anti-tumor efficacy in 4-T1 breast cancer-bearing mice. Paclitaxel-bromothiophene can be used for the study of breast cancer .
    Paclitaxel-bromothiophene
  • HY-N12209
    Neohelmanthicin A

    		Others Cancer
    Neohelmanthicin A (compound 3A) is a phenylpropanoid compound with antitumor activity. The IC50s of Neohelmanthicin A for inhibiting leukemia cell line EL4, breast cancer cell line S180 and breast cancer cell line MCF7 are 0.13 μM, 7 μM and 23 μM respectively .
    Neohelmanthicin A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: